
The trial will continue to evaluate change in kidney function over two years

The agreement includes a clinical-stage drug for the rare inherited metabolic disorder phenylketonuria

The Boston-based biotech will receive an upfront payment of $50m

The application is supported by results from a phase 3 trial demonstrating an exposure equivalence to the current standard of care for AML

The study for BMN 307 in genetic disease phenylketonuria will be paused while malignancies in mice are explored

Unable to recommend expanded use of tolvaptan